TrkB as a therapeutic target for ovarian cancer

被引:28
作者
Siu, Michelle K. Y. [1 ]
Wong, Oscar G. W. [1 ]
Cheung, Annie N. Y. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
BDNF; ovarian cancer; therapeutic target; TrkB; NEUROTROPHIC FACTOR ACTIVATION; FOLLICLE-STIMULATING-HORMONE; TYROSINE KINASE INHIBITOR; HEPATOCYTE GROWTH-FACTOR; PROTECTS NEUROBLASTOMA-CELLS; PHASE-I TRIAL; RECEPTOR TRKB; SIGNAL-TRANSDUCTION; CEP-751; KT-6587; AUTOPHOSPHORYLATION SITES;
D O I
10.1517/14728220903196787
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. Objective/methods: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. Results/conclusions: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer.
引用
收藏
页码:1169 / 1178
页数:10
相关论文
共 105 条
[51]   Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death [J].
Li, Z. ;
Zhang, J. ;
Liu, Z. ;
Woo, C. -W. ;
Thiele, C. J. .
CELL DEATH AND DIFFERENTIATION, 2007, 14 (02) :318-326
[52]   Inactivation of glycogen synthase kinase-3β contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells [J].
Li, Zhijie ;
Tan, Fei ;
Thiele, Carol J. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3113-3121
[53]   Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway [J].
Li, Zhijie ;
Thiele, Carol J. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (12) :1611-1621
[54]   Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrκB rescue of neuroblastoma cells from chemotherapy-induced cell death [J].
Li, ZJ ;
Jaboin, J ;
Dennis, PA ;
Thiele, CJ .
CANCER RESEARCH, 2005, 65 (06) :2070-2075
[55]   Trk C receptor signaling regulates cardiac myocyte proliferation during early heart development in vivo [J].
Lin, MI ;
Das, I ;
Schwartz, GM ;
Tsoulfas, P ;
Mikawa, T ;
Hempstead, BL .
DEVELOPMENTAL BIOLOGY, 2000, 226 (02) :180-191
[56]   Anoikis - Cancer and the homeless cell [J].
Liotta, LA ;
Kohn, E .
NATURE, 2004, 430 (7003) :973-974
[57]   Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor [J].
Marshall, JL ;
Kindler, H ;
Deeken, J ;
Bhargava, P ;
Vogelzang, NJ ;
Rizvi, N ;
Luhtala, T ;
Boylan, S ;
Dordal, M ;
Robertson, P ;
Hawkins, MJ ;
Ratain, MJ .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (01) :31-37
[58]   MOLECULAR AND BIOCHEMICAL-CHARACTERIZATION OF THE HUMAN TRK PROTO-ONCOGENE [J].
MARTINZANCA, D ;
OSKAM, R ;
MITRA, G ;
COPELAND, T ;
BARBACID, M .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (01) :24-33
[59]   NEW-PROTEIN FOLD REVEALED BY A 2.3-A RESOLUTION CRYSTAL-STRUCTURE OF NERVE GROWTH-FACTOR [J].
MCDONALD, NQ ;
LAPATTO, R ;
MURRAYRUST, J ;
GUNNING, J ;
WLODAWER, A ;
BLUNDELL, TL .
NATURE, 1991, 354 (6352) :411-414
[60]   Metastasis: a question of life or death [J].
Mehlen, P ;
Puisieux, A .
NATURE REVIEWS CANCER, 2006, 6 (06) :449-458